Parents are heartbroken as a beloved nappy rash cream - Metanium Nappy Rash Ointment - is discontinued. The product, known for its quick healing properties, has been a staple in changing bags for ...

Sanofi’s fiscal year 2024 results were in line with expectations, with a noteworthy performance in their Vaccines division, particularly driven by Beyfortus. This offset a slight ...

Management expects Beyfortus penetration to grow further with geographic expansion. Gross margin and R&D expenses are also anticipated to increase slightly in 2025, supported by preparations for u ...

Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s Beyfortus Drives Vaccine Sales Total vaccine sales increased 10.8% to €2.2 billion, driven by Beyfortus sales in Europe. Sales of flu ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

The company's research-and-development spending increased 24% on-year in the last quarter in an attempt to bring further blockbusters such as its respiratory syncytial virus vaccine Beyfortus to ...

Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...

Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 billion Vaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales ...

1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the ...

driven by Beyfortus sales in Europe Business EPS of €1.31, -11.0% at CER and -14.9% reported; IFRS EPS of €0.54 In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5 ...

Over-the-counter and home remedies typically treat it. Severe rashes that do not respond to basic care or last more than a few days may be due to an infection or underlying medical condition.